Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer

Pingbo XIE; Mingsheng LIU; Hongqing ZHOU; Shaomei WU; Tao SHAO; Feng GUO

doi:10.12259/j.issn.2095-610X.S20231208

Volume 44 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2023 > 44(12): 46-50

Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer[J]. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208

Citation:

Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer[J]. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208

Citation:

Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer[J]. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208

PDF( 707 KB)

Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer

doi: 10.12259/j.issn.2095-610X.S20231208

1.
Dept. of Urology，The 1st People’s Hospital of Qujing，Qujing Yunnan 655000
2.
Clinical Skills Training Center，Kunming Medical University，Kunming Yunnan 650500，China

Received Date: 2023-09-19
Available Online: 2023-12-19
Publish Date: 2023-12-25

Abstract

Abstract

Objective To evaluate the efficacy and safety of transurethral resection of Prostate（TURP） combined with endocrine therapy in patients with advanced prostate cancer. Methods A retrospective analysis was conducted on 87 cases of late-stage prostate cancer with dysuria admitted between January 2014 and December 2017. We divided them into 2 groups. TURP group （n = 48） received transurethral resection of prostate, followed by regular endocrine therapy. The control group （n = 39） was only given regular endocrine therapy. Comparative analysis of indicators such as prostate-specific antigen before and after treatment, maximum urinary flow rate, residual urine volume, International Prostate Symptom Score（IPSS）, and 5-year survival rate was performed between the two groups. Results Three months after TURP surgery, the symptoms of urinary difficulty significantly improved, and various indicators showed significant improvement compared to before the surgery. PSA levels also notably decreased compared to before the surgery. After 3 months of treatment, the TURP group showed significant improvements in IPSS, Qmax, RV, and PSA indicators compared to the control group（P < 0.05）. Both groups of patients experienced a gradual decrease in PSA levels after receiving standardized treatment. In the first 12 months of treatment, the PSA levels in the TURP group decreased more significantly compared to the control group, but after 12 months of treatment, the comparison difference was not statistically significant in the PSA levels between the two groups（P = 0.056）. A 5-year follow-up comparison of the two groups of patients revealed that there was no statistically significant difference in survival （P = 0.734）. Conclusion Transurethral resection of Prostate（TURP） combined with regular endocrine therapy can effectively improve the dysuria in prostate cancer patients, improve the quality of life of patients, and will not affect the five-year survival rate. TURP is a safe and effective treatment for advanced prostate cancer.
- Transurethral resection of prostate（TURP）,
- Endocrine therapy,
- Advanced prostate cancer,
- Five-year survival rate

FullText(HTML)

References(21)

References

[1]	Oelke M,Bachmann A,Descazeaud A,et al. EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction[J]. Eur Urol,2020,64(1):118-140.
[2]	Wong M C,Goggins W B,Wang H H,et al. Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries[J]. Eur Urol,2016,70(5):862-874. doi: 10.1016/j.eururo.2016.05.043
[3]	庞昆,梁清,陈波,等. 经尿道前列腺等离子电切术后晚期前列腺癌患者相关急性尿潴留的临床治疗方案研究[J]. 中华男科学杂志,2023,29(1):25-30. doi: 10.13263/j.cnki.nja.2023.01.004
[4]	黄智峰,钟喨,赖海标,等. 以尿潴留为首发表现的前列腺癌临床分析(附43例)[J]. 现代肿瘤医学,2019,27(7):1184-1188.
[5]	任虎,周伟,徐立. 经尿道姑息性手术治疗晚期前列腺癌的效果及对患者VAS评分的影响[J]. 中国性科学,2019,28(3):7-10.
[6]	何正宇,余闫宏,申杰,等. 1470nm激光汽化术通道法治疗晚期前列腺癌并膀胱出口梗阻[J]. 中华腔镜泌尿外科杂志(电子版),2018,12(6):411-414. doi: 10.3877/cma.j.issn.1674-3253.2018.06.012
[7]	黄海源,李金喜,陈政锦. 三联疗法治疗中晚期前列腺癌的临床观察[J]. 中国肿瘤外科杂志,2019,11(6):457-459.
[8]	莫益江,赵桂熔,刘文龙,等. 经尿道前列腺电切术联合雄激素剥夺治疗晚期前列腺癌的研究进展[J]. 汕头大学医学院学报,2022,35(3):185-187.
[9]	Forman J D,Order S E,Zinreich E S,et al. The correlation of pretreatment transurethral resection of prostatic cancer with tumor dissemination and disease-free survival. A univariate and multivariate analysis[J]. Cancer,1986,58(8):1770-1778. doi: 10.1002/1097-0142(19861015)58:8<1770::AID-CNCR2820580832>3.0.CO;2-U
[10]	Krupski T L,Stukenborg G J,Moon K,et al. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer[J]. BJU International,2010,106(10):.1477-1483. doi: 10.1111/j.1464-410X.2010.09356.x
[11]	Young S C,Jeman R,Dalsan Y,et al. Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: A propensity score matching study[J]. Journal of Cancer Research and Clinical Oncology,2018,144(4):.751-758. doi: 10.1007/s00432-018-2597-5
[12]	黄凤鸣,李晓红,梁勇. 伴骨转移前列腺癌患者内分泌治疗后出现早期CRPC的危险因素分析[J]. 中华男科学杂志,2018,24(8):690-694.
[13]	王林,庞鹏,刘泽龙,等. 经尿道前列腺电切术对前列腺癌合并膀胱出口梗阻患者前列腺症状指标、血清学指标及生存情况的影响[J]. 癌症进展,2022,20(11):1168-1171.
[14]	邱腾,胡小桃. 经尿道前列腺电切术联合内分泌治疗晚期前列腺癌的临床疗效及不良反应分析[J]. 滨州医学院学报,2019,42(6):421-423.
[15]	Bai D S,Chen P,Qian J J,et al. Effect of marital status on the survival of patients with gallbladder cancer treated with surgical resection: A population-based study[J]. Oncotarget,2017,8(16):26404-26413. doi: 10.18632/oncotarget.15476
[16]	崔宁,马永康,马德青,等. 经尿道前列腺癌电切术联合手术去势对前列腺癌患者前列腺功能及TNF-α、IGF-1、PSA水平的影响[J]. 临床医学研究与实践,2023,8(6):62-64. doi: 10.19347/j.cnki.2096-1413.202306018
[17]	许宁,甄晓玲,张祥. 经尿道前列腺癌电切术患者血清VEGF、TGF-β1的水平变化及其临床意义[J]. 海军医学杂志,2019,40(2):147-150. doi: 10.3969/j.issn.1009-0754.2019.02.018
[18]	Pelletier J,Cyr S J,Julien A S,et al. Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer[J]. Urol Oncol,2018,36(8):363.e7-363.e11. doi: 10.1016/j.urolonc.2018.05.004
[19]	周俊,陈如,马锋. 经尿道前列腺等离子电切术联合内分泌疗法治疗晚期前列腺癌合并膀胱出口梗阻的临床疗效观察[J]. 国际泌尿系统杂志,2020,40(2):239-242.
[20]	Crain D S, Amling C L, Kane C J. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer[J]. J Urol, 2004, 171（2 Pt 1）: 668-671.
[21]	Meeks J J,Habermacher G M,Le B,et al. Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP[J]. Urology,2008,72(4):948.e11-12. doi: 10.1016/j.urology.2008.01.007

Relative Articles(20)

Relative Articles

[1]	Wei WANG, Sheng LIU, Hongqing ZHOU, Mingsheng LIU, Pingbo XIE, Feng GUO, Guanyu CHEN. Clinical Efficacy of Immediate Radical Surgery for Locally Advanced Prostate Cancer. Journal of Kunming Medical University, 2025, 46(1): 43-50. doi: 10.12259/j.issn.2095-610X.S20250106
[2]	Longguo DAI, Yu BAI. Research Progress of Cytoreductive Treatment for Metastatic Prostate Cancer. Journal of Kunming Medical University, 2023, 44(1): 135-139. doi: 10.12259/j.issn.2095-610X.S20230103
[3]	Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer. Journal of Kunming Medical University, 2023, 44(10): 180-188. doi: 10.12259/j.issn.2095-610X.S20231020
[4]	Bin ZHAO, Yuanpeng DUAN, Guoying ZHANG, Chengwei BI, Libo YANG, Zhiyu SHI, Yong YANG, Jianpeng ZHANG, Ting GAO. CircRNA EZH2 Promotes Proliferation and Migration of Prostate Cancer Cells by Regulating miR-30c-5p. Journal of Kunming Medical University, 2022, 43(7): 25-32. doi: 10.12259/j.issn.2095-610X.S20220731
[5]	Wen-jing SUN, Man-ting HU, Na LI, Fei GE, Wen-lin CHEN, Yang LIU. Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer. Journal of Kunming Medical University, 2021, 42(7): 143-149. doi: 10.12259/j.issn.2095-610X.S20210724
[6]	Wang Yang . Comparison of Short-term Efficacy between Transurethral Plasmakinetic Enucleation and Holmium Laser Enucleation in the Treatment of Benign Prostatic Hyperplasia. Journal of Kunming Medical University,
[7]	Ma Yin Rui . . Journal of Kunming Medical University,
[8]	Li Xiao Tao . . Journal of Kunming Medical University,
[9]	Yang Jian Hua . . Journal of Kunming Medical University,
[10]	Shen Hong . . Journal of Kunming Medical University,
[11]	Ke Kun Bin . . Journal of Kunming Medical University,
[12]	Cao Shao Dang . . Journal of Kunming Medical University,
[13]	Lei Jing . . Journal of Kunming Medical University,
[14]	Sun Jian Wei . . Journal of Kunming Medical University,
[15]	Liu Peng Jie . . Journal of Kunming Medical University,
[16]	Li Yi . . Journal of Kunming Medical University,
[17]	. . Journal of Kunming Medical University,
[18]	Ruan Dian Sheng . . Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	胡振宇，解福军，孙燕滨. 经尿道前列腺电切术在中晚期前列腺癌中的应用价值. 系统医学. 2024(13): 130-133 .
2.	徐新宇，彭煜，朱文静. 前列腺癌内分泌治疗的研究进展. 河南大学学报(医学版). 2024(06): 391-395 .